DTA突变对新诊断急性髓系白血病患者的预后价值
[Prognostic Value of DTA Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia].
发表日期：2024 Aug
作者：
Hui-Juan Chen, Yang Cao, Ying-Jie Miao, Yi-Fang Zhou, Yue Liu, Wei-Ying Gu
来源：
Disease Models & Mechanisms
摘要：
探讨DTA（DNMT3A、TET2、ASXL1）基因突变对非M3急性髓系白血病（AML）患者预后的意义。 收集2018年1月至2018年1月至常州市第一人民医院住院的180例初诊AML患者的临床资料。对2022年4月进行了回顾性分析。采用二代测序技术检测患者150个基因突变，并采用log-rank检验和Cox回归模型分析预后因素。180例AML患者中83例（46.1%）检测到DTA基因突变。与无 DTA 突变的患者相比，有 DTA 突变的患者年龄明显较大 (P < 0.001)。 DTA突变组的中位总生存（OS）时间和无病生存（DFS）时间显着短于无DTA突变组（均P < 0.05）。多变量分析显示，年龄≥60岁（P < 0.001）、DTA突变（P = 0.018）和中危（相对于有利风险）（P = 0.005）是AML患者OS的独立危险因素。 DTA突变患者年龄相对较大，中位OS时间和DFS时间较短，预后较差。
To investigate the prognostic significance of DTA (DNMT3A, TET2, ASXL1 ) gene mutations in patients with non-M3 acute myeloid leukemia (AML).The clinical data of 180 newly diagnosed AML patients hospitalized in the First People's Hospital of Changzhou from January 2018 to April 2022 were retrospectively analyzed. Next-generation sequencing technology was used to detect 150 gene mutations in the patients, and log-rank tests and Cox regression models were used to analyze the prognostic factors.DTA gene mutations were detected in 83 (46.1%) of 180 AML patients. Compared to patients without DTA mutations, patients with DTA mutations were significantly older (P < 0.001). The median overall survival (OS) time and disease-free survival (DFS) time in the DTA mutation group were significantly shorter than those in the group without DTA mutation (both P < 0.05). Multivariate analysis showed that age ≥ 60 years (P < 0.001), with DTA mutation (P =0.018), and intermediate-risk (relative to favorable-risk) (P =0.005) were independent risk factors for OS in AML patients.AML patients with DTA mutations are relatively older, with shorter median OS time and DFS time, and poor prognosis.